Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval
Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to an expanded range of patients.
The FDA approved the Boulder-based company (Nasdaq: CLVS) selling rucaparib as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile.
That means more women with…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Greg Avery Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Epithelial Cancer | Fallopian Tube Cancer | Food and Drug Administration (FDA) | Genetics | Health Management | Marketing | Ovarian Cancer | Ovaries | Peritoneal Cancer | Women